Alnylam Pharmaceuticals (ALNY) is trading higher today as the market continues to re-rate the company’s transthyretin (TTR) franchise—particularly AMVUTTRA in ATTR cardiomyopathy (ATTR-CM)—following recent investor communications and fresh medical-meeting visibility. In late March, Alnylam’s messaging around ATTR-CM commercialization reinforced the view that diagnosis and treatment rates can expand meaningfully, keeping the company’s cardiology opportunity front and center.

The biggest driver behind the positive tone is sustained confidence in AMVUTTRA’s ATTR-CM launch trajectory and Alnylam’s 2026 outlook. Alnylam has reiterated 2026 TTR revenue guidance of $4.4 billion to $4.7 billion, while analysts have pointed to the company’s initial 2026 total product sales guidance of $4.9 billion to $5.3 billion as an upside-leaning anchor for expectations.

With ALNY already priced as a premium large-cap biotech, incremental confidence in durable ATTR-CM demand matters because it supports a longer runway of high-growth, high-margin TTR revenues. Investors are also watching competitive dynamics in ATTR and the evolving standard of care, where category growth and earlier diagnosis could expand the addressable market rather than simply shift share.

Near-term, investors will watch for additional physician-demand indicators, payer/access updates, and any new data disclosures that further clarify AMVUTTRA’s differentiation in ATTR-CM. On the Street, additional price-target changes and rating moves could act as secondary catalysts if new datapoints strengthen confidence in the 2026 ramp.